Kyverna Therapeutics reports Q3 2026 loss, EPS beat and rolling BLA submission
Kyverna Therapeutics posted a net loss that widened 14% year over year in the third quarter of 2026, with total operating expenses up 11%. Research and development costs fell 11% while general and administrative expenses jumped 92%. The company reported GAAP diluted EPS of -$0.68, beating estimates by $0.01, and completed a rolling BLA submission for miv-cel in the SPS pathway. It expects to finish patient enrollment in its Phase 3 trial by mid‑2027 and held $170.6 million in cash and equivalents at quarter end.
Why it matters
The EPS beat suggests the loss was slightly less than analysts expected, which may support the stock price. The cash balance and upcoming trial enrollment indicate the company has sufficient liquidity to fund its development program.
Key facts
- 1Net loss widened 14% year over year. tradingview.com
- 2Total operating expenses rose 11% versus the prior quarter. tradingview.com
- 3Research and development expenses fell 11% versus the prior quarter. tradingview.com
- 4General and administrative expenses increased 92% versus the prior quarter. tradingview.com
- 5GAAP diluted EPS was -$0.68, beating estimates by $0.01. seekingalpha.com
- 6Cash and equivalents totaled $170.6 million as of September 30, 2026. seekingalpha.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.